Sperm Donation & Therapeutic Donor Insemination: Complete Treatment Guide — Cost, Top Hospitals & Success Rates | MyMedicPlus

Sperm donation is a process by which a man voluntarily provides a semen sample for use by individuals or couples who require donated gametes to conceive. The donated sperm may be used in therapeutic donor insemination (TDI) — also called donor sperm intrauterine insemination (DS-IUI) — or in in vitro fertilisation with donor sperm (DSP-IVF), including ICSI (intracytoplasmic sperm injection) where indicated.

Sperm donation is one of the longest-established assisted reproduction technologies, with the first reported human pregnancy from donor insemination dating to the 1880s. Modern sperm donation is conducted within a tightly regulated framework of infectious disease screening, genetic testing, cryopreservation, and informed consent — standards established and enforced by regulatory bodies including the Human Fertilisation and Embryology Authority (HFEA) in the United Kingdom, the Food and Drug Administration (FDA) and American Association of Blood Banks (AABB) in the United States, and equivalent national authorities across the European Union (EU Directive 2004/23/EC).

Sperm donation enables conception for individuals and couples who cannot use the male partner's own sperm, or who do not have a male partner. Principal recipient groups include: couples where the male partner has severe azoospermia or untreatable infertility; couples at risk of transmitting a serious genetic condition; single women choosing to parent alone; and same-sex female couples. In the United Kingdom, the HFEA oversees all licensed fertility clinics, and since April 2005, all UK sperm donors must consent to having their identity disclosed to donor-conceived offspring when those individuals reach the age of 18 (the "identity-release" or "open-ID" donor system). Anonymous donation is no longer permitted for sperm used in UK treatment.

Clinics are required to record all donor information in a centralised register, ensuring traceability and enabling donor-conceived individuals to access their genetic heritage in adulthood.

Donor sperm treatment is indicated across a range of medical, genetic, and social circumstances:

• Non-obstructive azoospermia (NOA): The most common medical indication. Failure of sperm production due to testicular failure (primary hypogonadism, Klinefelter syndrome 47,XXY, Sertoli cell-only syndrome, maturation arrest, prior chemotherapy/radiotherapy gonadotoxicity, or idiopathic causes). In NOA, surgical sperm retrieval (TESA/microTESE) has a 30–60% sperm retrieval rate; when surgical retrieval fails or is declined, donor sperm provides the only route to biologically related offspring for the female partner.
• Severe oligospermia or asthenoteratospermia: Markedly reduced sperm count, motility, or morphology beyond the reach of ICSI with partner sperm — donor sperm IVF-ICSI may be recommended.
• Genetic contraindications: When the male partner is a carrier of a serious autosomal dominant or X-linked genetic disorder that carries >50% transmission risk and for which preimplantation genetic testing (PGT) is not feasible or acceptable. Examples include Huntington's disease, myotonic dystrophy, severe haemophilia, or fragile X syndrome.
• Transmissible infectious disease: Historically, men with HIV infection were excluded from providing sperm; with modern antiretroviral therapy achieving undetectable viral loads, sperm donation risk is now negligible in virologically suppressed individuals, though regulatory approaches vary by country.
• Single women: Women choosing to conceive without a male partner account for an increasing proportion of donor sperm recipients in many Western countries.
• Same-sex female couples: Both partners may use donor sperm — one carries the pregnancy, the other may provide the egg in reciprocal IVF (RIVF) arrangements.
• Recurrent pregnancy loss with male chromosomal factor: Where the male partner carries a chromosomal rearrangement contributing to recurrent miscarriage and PGT is not appropriate or effective.

Sperm donation involves rigorous eligibility assessment for both donors and recipients, governed by HFEA (UK), FDA (US), and AABB/WHO standards.

Donor Eligibility Requirements:

• Age: Typically 18–40 years. HFEA guidance suggests the upper limit of 41 to minimise age-related chromosomal anomaly risk.
• Semen analysis: Must meet WHO 2021 reference values: sperm concentration ≥16 million/mL (post-processing), total motility ≥42%, progressive motility ≥30%, morphology ≥4% (Kruger strict criteria). Post-thaw motility must be adequate for the intended treatment route.
• Infectious disease screening: Mandatory testing for HIV-1/2 (NAT and serology), hepatitis B (HBsAg, anti-HBc), hepatitis C (anti-HCV and NAT), syphilis, HTLV I/II, CMV (IgG/IgM — CMV-positive donors matched only to CMV-positive or accepting recipients), gonorrhoea, chlamydia. Re-testing after a minimum 6-month quarantine period is mandatory before cryopreserved sperm can be released for use (HFEA and FDA requirement).
• Genetic screening: Karyotype (to exclude chromosomal rearrangements and sex chromosome aneuploidies); carrier testing for cystic fibrosis (CFTR), spinal muscular atrophy (SMN1), and fragile X (FMR1) at minimum; extended expanded carrier screening (ECS) panels (100+ conditions) are increasingly used at commercial sperm banks.
• Medical and family history: Three-generation pedigree reviewed by a clinical geneticist to exclude hereditary conditions; psychological assessment to evaluate motivation and capacity for informed consent.

Recipient Assessment: Uterine cavity assessment by hysteroscopy or saline infusion sonography (SIS); tubal patency (HSG or laparoscopy/dye) before IUI; ovarian reserve assessment (AMH, antral follicle count); review of all medical, obstetric, and gynaecological history; psychological counselling (mandatory in the UK under HFEA licence requirements).

Donor sperm can be used in two principal treatment pathways, selected based on the recipient's fertility status, age, and clinical assessment:

Therapeutic Donor Insemination (TDI) / Donor Sperm IUI: Prepared donor sperm is injected directly into the uterine cavity (intrauterine insemination, IUI) at the time of ovulation, maximising sperm proximity to the egg. Treatment may be performed in a natural cycle (monitoring ovulation with LH kits or ultrasound) or a stimulated cycle (low-dose FSH injections to recruit 1–2 dominant follicles). IUI is the least invasive option and is appropriate for recipients with patent fallopian tubes and adequate ovarian reserve. Up to 6 IUI cycles are typically recommended before escalating to IVF.

IVF with Donor Sperm (DSP-IVF) and ICSI: Indicated when IUI has failed, when the recipient has tubal occlusion, advanced maternal age, or severe diminished ovarian reserve (where success rates with IUI are very low). The recipient undergoes controlled ovarian hyperstimulation (COH) with FSH/LH injections, followed by egg collection under ultrasound guidance and sedation, fertilisation of eggs with donor sperm (conventional IVF or ICSI), embryo culture to blastocyst stage (Day 5), and fresh or frozen embryo transfer. Surplus embryos are cryopreserved (vitrification) for future cycles.

Sperm Cryopreservation and Quarantine: All donated sperm is cryopreserved at -196°C in liquid nitrogen. A minimum 6-month quarantine is required before release, during which the donor undergoes repeat infectious disease testing. Cryopreservation enables sperm banking from international donors and ensures supply reliability.

Identity-Release Donors (HFEA 2005): Under the Human Fertilisation and Embryology (Disclosure of Donor Information) Regulations 2004, all sperm donors who donated in UK-licensed clinics after April 1, 2005 have consented to their identifiable information being released to donor-conceived offspring upon their 18th birthday if requested. The HFEA Register holds all donor information centrally. Donor-conceived individuals born from donors prior to 2005 may be able to access non-identifying information through the Donor Sibling Registry or voluntary re-registration.

HFEA 10-Family Limit: The HFEA limits use of any one donor's sperm to a maximum of 10 families in the UK (regardless of the number of children born to each family), reducing half-sibling networks and psychosocial risks.

Donor sperm treatment offers clear clinical benefits for individuals and couples who would otherwise be unable to conceive, with well-established success rate data from large HFEA and CDC ART registry datasets:

Clinical Success Rates:

• Donor sperm IUI (TDI): Cumulative pregnancy rate per cycle approximately 10–15%, varying with age, stimulation protocol, and endometrial receptivity. Cumulative rates over 6 cycles reach 50–60% in women under 35 with normal tubal function.
• IVF with donor sperm: Live birth rate per embryo transfer approximately 30–40% per cycle in women under 35; declining with maternal age to ~15–20% at age 40–42. Use of donor eggs combined with donor sperm (double donation) in older recipients or those with poor ovarian reserve further optimises outcomes.
• Frozen versus fresh embryo transfer: Vitrification technology has made frozen embryo transfer (FET) essentially equivalent to fresh transfer in terms of live birth rates, with the added benefit of allowing endometrial optimisation in a separate cycle.

Psychosocial Benefits: Access to donor sperm treatment enables single women and same-sex female couples to achieve parenthood — a fundamental aspect of reproductive autonomy. Legal frameworks in the UK (HFEA 1990, as amended 2008) provide clear parental status to the birth mother and, where applicable, her female partner or consenting male partner at time of conception, giving families created through donor sperm clear legal certainty.

Genetic Health Benefits: Rigorous expanded carrier screening of donors (150+ conditions at leading US sperm banks) and mandatory karyotyping substantially reduce — though do not eliminate — the risk of transmitting a serious inherited disorder to donor-conceived children.

Identity and Wellbeing: Research studies consistently show that the majority of donor-conceived individuals raised in open, informed family environments show psychological wellbeing equivalent to naturally conceived peers. The identity-release framework (HFEA 2005) is associated with improved psychological outcomes for donor-conceived persons compared to historical anonymous donation.

Donor sperm treatment is generally safe, but several medical, genetic, and psychosocial risks warrant careful consideration and pre-treatment counselling.

Medical Risks:

• Ovarian hyperstimulation syndrome (OHSS): Risk during stimulated IUI or IVF cycles, particularly in young women with polycystic ovary syndrome (PCOS) or high antral follicle count. Ranges from mild (bloating, discomfort) to severe (ascites, thrombosis, respiratory compromise). GnRH antagonist protocols and agonist trigger substantially reduce severe OHSS rates.
• Multiple pregnancy: Stimulated IUI cycles carry a 10–20% twin rate; current HFEA guidelines recommend elective single embryo transfer (eSET) in IVF to minimise multiple pregnancy risk (which carries higher maternal, obstetric, and neonatal morbidity).
• Infectious transmission: Despite rigorous screening, no testing programme eliminates all transmission risk — window period HIV or HCV infection, emerging pathogens not yet included in panels, and laboratory error represent residual risk.
• Genetic condition transmission: No carrier screen covers all known pathogenic variants; rare de novo mutations are not preventable. The risk of an undetected inherited condition from screened donors is low but not zero.

Psychosocial and Ethical Considerations:

• Donor-conceived persons' right to identity: The ethical imperative to disclose donor conception to children at an appropriate age is supported by the majority of psychological research, HFEA guidance, and international bodies. Late or non-disclosure is associated with higher rates of identity-related difficulties.
• Donor psychological wellbeing: Donors should receive psychological counselling to understand the implications of genetic parenthood, including future contact requests from donor-conceived offspring at age 18 under the HFEA identity-release framework.
• Cross-border reproductive care: International patients sometimes travel to access lower-cost or less restrictive donor sperm services; differences in regulatory standards (e.g., anonymous donation in Spain, France historically) create complex legal and ethical issues around donor offspring rights.

Follow-up care following donor sperm treatment spans the immediate post-treatment period through pregnancy confirmation and beyond, and includes psychosocial support for the recipient family over the longer term.

Post-Insemination / Post-Transfer Monitoring:

• Serum beta-hCG pregnancy test 14 days after IUI or 10–14 days after embryo transfer
• Repeat hCG at 48 hours to confirm doubling (indicating viable intrauterine pregnancy)
• Early viability ultrasound at 6–7 weeks gestation to confirm intrauterine location, cardiac activity, and dating
• Luteal phase support (progesterone pessaries or injections) for IVF cycles, typically continuing to 10–12 weeks

Obstetric Care: Pregnancies achieved through IVF (donor sperm or otherwise) are considered higher-risk obstetric pregnancies in many guidelines, warranting earlier antenatal booking, additional ultrasound monitoring, and heightened attention to maternal complications (gestational hypertension, preeclampsia, gestational diabetes). Dating scan (11–14 weeks combined first-trimester screening) and anomaly scan (20 weeks) proceed as for all pregnancies.

Psychological Support and Counselling: The HFEA mandates that all recipient patients receive implications counselling before treatment — an opportunity to explore the full emotional, social, legal, and practical implications of having a donor-conceived child. Ongoing access to counselling throughout the treatment journey and after the birth of a donor-conceived child is strongly recommended. Key areas include: how and when to tell the child about their origins; managing extended family and community disclosure; anticipated questions from the child at different developmental stages; and future management of donor sibling relationships.

HFEA Register and Donor Information Access: Recipients should be informed that their treatment details and the donor's information are recorded on the confidential HFEA Register. At age 18, donor-conceived individuals can apply to the HFEA for identifying donor information. Families can also register voluntarily with the Donor Sibling Registry (UK and US) to facilitate voluntary sibling connections.

The cost of donor sperm treatment varies considerably between countries, clinic types, and treatment pathways. Understanding the full cost structure enables effective financial planning.

Sperm Bank and Donor Costs:

• Donor recruitment compensation: HFEA (UK) permits payment of reasonable expenses only (up to approximately GBP 35 per clinic visit); this is not payment for sperm. US donors at commercial sperm banks typically receive USD 50–150 per accepted donation, with monthly earnings of USD 500–1,500 for active donors.
• Sperm vial purchase: Importing donor sperm from licensed commercial US or European banks costs approximately USD 400–1,200 per vial (ICI-ready or IUI-ready preparation). Multiple vials are often purchased to ensure supply for several treatment cycles.

Treatment Costs (United Kingdom):

• NHS funding for donor sperm IUI is available in some Clinical Commissioning Group (CCG) areas in England, subject to eligibility criteria (age, BMI, previous children). Most patients fund privately.
• Private donor sperm IUI: Approximately GBP 800–1,500 per cycle (monitoring, insemination, sperm preparation, medications extra)
• Private IVF with donor sperm: Approximately GBP 4,500–8,000 per cycle (excluding medication ~GBP 1,000–2,500 and sperm purchase)

Treatment Costs (United States):

• Donor sperm IUI: Approximately USD 700–2,000 per cycle
• IVF with donor sperm: Approximately USD 12,000–20,000 per cycle (excluding medication and donor sperm purchase)
• Mini/natural IVF with donor sperm: Lower stimulation cost but reduced egg yield — approximately USD 5,000–10,000

Medical Tourism: IVF with donor sperm is available at internationally accredited fertility clinics in Spain, Czech Republic, Greece, and Cyprus at EUR 3,000–6,000 per cycle; in India and Thailand from USD 3,000–6,000. These jurisdictions allow anonymous donation (unlike the UK), which is an important ethical consideration for prospective parents and future offspring.

Before pursuing donor sperm treatment, patients should be aware of alternative approaches that may enable conception using the male partner's own gametes, as well as non-treatment alternatives.

Surgical Sperm Retrieval Techniques:

• TESA (Testicular Sperm Aspiration): A fine needle is inserted into the testis under local anaesthesia to aspirate testicular tissue; suitable for obstructive azoospermia. Simple, low-risk outpatient procedure.
• Micro-TESE (Microsurgical Testicular Sperm Extraction): Operating microscope-guided exploration of testicular tubules to identify and retrieve rare spermatozoa in non-obstructive azoospermia. Sperm retrieval rates of 40–60% in appropriately selected NOA patients. Retrieved sperm used with ICSI.
• PESA (Percutaneous Epididymal Sperm Aspiration): Fine needle aspiration from the epididymis; suitable for obstructive azoospermia (e.g., post-vasectomy, congenital absence of vas deferens).

Preimplantation Genetic Testing (PGT): For couples where the male partner carries a serious genetic condition, IVF with PGT-M (monogenic) allows selection of unaffected embryos for transfer — avoiding the need for donor sperm in many cases where the concern is genetic disease transmission rather than sperm production.

Vasectomy Reversal: For men who had vasectomy and desire biological paternity, microsurgical vasectomy reversal (vasovasostomy or vasoepididymostomy) has success rates of 40–90% depending on time since vasectomy, with higher success rates when performed within 10 years of the original procedure.

Embryo Donation: Couples with surplus cryopreserved embryos may donate them to recipients who need both egg and sperm donation. This option is available at HFEA-licensed clinics in the UK (Embryo Donation register) and provides a complete, pre-formed embryo rather than requiring separate egg retrieval and fertilisation.

Adoption and Foster Care: For those who prefer not to pursue assisted reproduction, adoption and fostering provide alternative pathways to parenthood. Legal parental frameworks are well-established and may be more accessible depending on personal, religious, or ethical preferences.